Background-ACE inhibition (ACEI) attenuates post-myocardial infarction (MI) LV remodeling, but the effects of angiotensin II type 1 receptor (AT 1 ) antagonism alone or in combination with ACEI are unclear. Accordingly, we investigated the effects of AT 1 antagonism, ACEI, and their combination in a well-characterized ovine postinfarction model. Methods and Results-Beginning 2 days after transmural anteroapical MI, 62 sheep were treated with 1 of 5 treatment regimens: no therapy (control, nϭ12), standard-dose ACEI (sACEI; ramipril 10 mg/d, nϭ14), high-dose ACEI (hACEI; ramipril 20 mg/d, nϭ8), AT 1 blockade (losartan 50 mg/d, nϭ13), and combination therapy with sACEIϩAT 1 blockade (CT; ramipril 10 mg/dϩlosartan 50 mg/d, nϭ15). MRI was performed before and 8 weeks after MI to quantify changes in LV end-diastolic and end-systolic volume indices (⌬EDVI, ⌬ESVI) and ejection fraction (⌬EF). Change in regional percent intramyocardial circumferential shortening in noninfarcted segments adjacent to the infarct (Adj ⌬%S) was measured by tagged MRI. CT resulted in the most marked blunting of LV remodeling: ⌬ESVI (ϩ1.0Ϯ0.4, ϩ0.7Ϯ0.4, ϩ0.6Ϯ0.3 †, ϩ0.9Ϯ0.5, and ϩ0.4Ϯ0.2* mL/kg); ⌬EDVI (ϩ0.9Ϯ0.4, ϩ0.7Ϯ0.5, ϩ0.6Ϯ0.5, ϩ0.9Ϯ0.5, and ϩ0.4Ϯ0.3 ‡ mL/kg); ⌬EF (Ϫ24Ϯ7, Ϫ18Ϯ6, Ϫ14Ϯ7 †, Ϫ18Ϯ10, and Ϫ11Ϯ9* %); and Adj ⌬%S (Ϫ8Ϯ4, Ϫ7Ϯ3, Ϫ5Ϯ3, Ϫ5Ϯ3, and Ϫ2Ϯ3* %) for Control, sACEI, hACEI, AT 1 blockade, and CT, respectively (*PϽ0.04 versus sACEI, AT 1 blockade, and control; †PϽ0.05 versus control; ‡PϽ0.002 versus AT 1 blockade and control). EDVI and ESVI at 8 weeks after MI were smallest with CT (PϽ0.02 versus all).
L eft ventricular (LV) remodeling after myocardial infarction is characterized by infarct expansion, 1,2 myocyte hypertrophy, 3, 4 myocyte slippage, 5 lengthening of noninfarcted segments, 6 -8 global ventricular dilatation, 7 and dysfunction in noninfarcted regions adjacent to the infarct. 8 ACE inhibition (ACEI) attenuates postinfarction LV remodeling in experimental models 9 -11 and improves survival in humans. 12 Although ACEI blunts postinfarction LV remodeling, the mechanisms involved remain incompletely understood, and the degree of attenuation is incomplete. 13 Experimental evidence indicates that the influence of ACEI on LV remodeling may involve both direct angiotensin II (Ang II) effects acting via a variety of Ang II receptor subtypes and indirect effects on kallikrein-kinin systems. 14, 15 Alternative (non-ACE) enzymatic pathways for the production of Ang II have also been demonstrated within the heart, which may limit the effectiveness of ACEI. 16,16a Combined ACEI and Ang II type 1 receptor (AT 1 ) blockade has also been shown to provide enhanced benefits in a pacing model of congestive heart failure. 17 The addition of AT 1 blockade to recommended or maximally tolerated ACEI was recently shown to improve exercise capacity and reduce symptoms in patients with heart failure. 18 Jorde et al 19 recently found, however, that maximally recommended doses of ACEI may be inadequate and that very-high-dose ACEI provided experimental hemodynamic effects similar to those with combined AT 1 blockade and standard-dose ACEI in patients with heart failure. The effects of combined ACEI and AT 1 antagonism on postinfarction LV remodeling are uncertain. Accordingly, a wellcharacterized postinfarction model was used to determine the effects of combined ACEI and AT 1 antagonism on postinfarction LV remodeling and LV systolic function.
Methods

Experimental Protocol
In 67 female Q fever-negative Dorset sheep (40 to 45 kg), a left thoracotomy was performed with ligation of the left anterior descending coronary artery and its second diagonal branch to create a moderate-size transmural anteroapical infarction as previously described. 4, 8, 11, 20, 21 Sixty-two sheep completed the protocol (5 sheep died of ventricular arrhythmia on the day of infarction). All procedures followed were in accordance with the "Position of the American Heart Association on Research Animal Use," adopted by the Association in November 1984, and the Institutional Animal Care and Use Committee at Allegheny General Hospital. Beginning on day 2 after MI, animals were treated with no therapy (Control, nϭ12), ramipril 10 mg PO QD (standard-dose ACEI; sACEI, nϭ14), ramipril 10 mg PO BID (high-dose ACEI; hACEI, nϭ8), losartan 25 mg PO BID (AT 1 , nϭ13), or combination therapy with ramipril 10 mg PO QD and losartan 25 mg PO BID (CT, nϭ15). Previous work in this model has demonstrated that the 10-mg/d dose of ramipril inhibits circulating ACE activity and reliably attenuates LV remodeling. 11 The 20-mg/d dose of ramipril was also studied to determine differential effects of high-dose ACEI. The dose of losartan was selected on the basis of its ability to blunt by Ͼ50% the pressor response to a 10-minute intravenous infusion of Ang II (at a dose that consistently increased mean arterial pressure by 30% in this animal model) and to maintain this effect against repeated challenges of Ang II up to 11 hours after the last dosing. Serial blood pressures (with an automated pediatric blood pressure cuff in the left forelock of the standing animal) and heart rates were recorded daily for 5 days and then weekly thereafter. Left atrial pressures 8 weeks after MI were also measured.
Magnetic Resonance Imaging
MRI was performed at baseline (preinfarction) and at 8 weeks after infarction. Before the imaging sessions, all animals were premedicated intravenously with diazepam (1 mg), penicillin (22 000 U/kg), and gentamicin (3 mg/kg). Intravenous 5% guaifenesin and 500 mg of ketamine provided heavy sedation during imaging. Intubation, mechanical ventilation, nasogastric suction, and ECG monitoring were performed. The anesthetized, ventilated animal was placed in the right lateral decubitus position on a phased-array surface coil in a Siemens 1.5-T scanner, and ECG gating was initiated.
Multiple-breath-hold, segmented-k-space, multiphase gradientecho cine series were performed (for measurement of LV mass [LVM], end-systolic and end-diastolic volumes [ESV and EDV], and ejection fraction [EF]) spanning the LV from apex to base. Imaging parameters were repetition time (TR) 60 ms (with view-sharing, yielding a 30-ms temporal resolution), echo time (TE) 4.8 ms, slice thickness 7 mm, 128ϫ256 matrix, and 25-cm field of view, yielding a final interpolated pixel size of 0.95 mm 2 . Two-chamber and 4-chamber apical long-axis images were also obtained. For analysis of regional intramyocardial function, breath-hold-tagged short-axis images were obtained spanning the LV from apex to base as previously described. 4, 21 Imaging parameters included 7-mm slice thickness, 7-mm tag stripe separation, TR 70 ms (with view-sharing, yielding a 35-ms temporal resolution), TE 4 ms, 128ϫ56 matrix, 25-cm field of view, final interpolated pixel size 0.95 mm 2 , and 2 signal averages. The ventilator was held at end expiration during all breath-hold sequences.
MR Image Analysis
LVM, ESV, EDV, and EF were measured from stacked short-axis cine slices by blinded image analysts using Siemens Imageview software (Siemens Corporate Research) and published techniques. 4,21 LVM, ESV, and EDV were then indexed to body weight in kilograms (LVMI, ESVI, and EDVI). Infarct size at 8 weeks was measured as the mass of thinned infarcted tissue from interleaved end-diastolic short-axis images and was expressed as a percentage of myocardial mass by previously published techniques that have been demonstrated to correlate highly with a pathological "gold standard" in this model. 8 Regional percent intramyocardial segment shortening (%S) from stacked short-axis tagged images was measured by a single blinded observer using a software package (VIDA, © University of Iowa) on a SUN workstation by previously reported methods. 4, 8, 11, 21 Interstripe distances were measured at end systole (L es ) and end diastole (L ed ), and %S was calculated as %Sϭ100(L ed ϪL es )/ L ed . %S was measured at subendocardial and subepicardial sites in segments located within infarcted, adjacent, and remote regions. As defined in previous studies, adjacent regions are those within 2 cm of the clearly demarcated infarct border, and remote regions are Ͼ2 cm removed. 4, 8, 11, 21 Preinfarct baseline data were analyzed by apex-tobase location and matched to postinfarct images by previously published techniques. Regional myocardial wall thickness (infarct, adjacent, and remote) was measured at 8 weeks after MI from 4-chamber long-axis end-diastolic cine MRI images by blinded observers using previously published techniques. 8
Statistical Analysis
Changes between baseline and 8 weeks after MI within each treatment group in blood pressure, heart rate, LVMI, EDVI, ESVI, EF, and regional %S were assessed. Infarct mass, left atrial pressure, and end-diastolic regional myocardial wall thickness were also compared between groups by ANOVA. Data are presented as group mean valuesϮSD, with a value of PϽ0.05 defined as significant.
Results
Infarct size was similar for all groups (Control, 23Ϯ8%; sACEI, 23Ϯ7%; hACEI, 19Ϯ2%; AT 1 , 22Ϯ5%; and CT, 23Ϯ6%; PϭNS for all). Baseline, 4-week post-MI, and 8-week post-MI mean blood pressures were similar for Control, sACEI, hACEI, AT 1 , and CT, respectively: 73Ϯ14, 73Ϯ15, 72Ϯ16, 72Ϯ17, and 72Ϯ9 mm Hg at baseline; 71Ϯ8, 72Ϯ9, 70Ϯ13, 71Ϯ12, and 69Ϯ8 mm Hg at 4 weeks; and 71Ϯ12, 76Ϯ7, 71Ϯ13, 69Ϯ12, and 70Ϯ9 mm Hg at 8 weeks (PϭNS for all). Baseline heart rates were similar, but infarcted controls had a higher heart rate than sACEI, hACEI, AT 1 , or CT at 8 weeks after MI, respectively: 124Ϯ17*, 102Ϯ12, 104Ϯ15, 111Ϯ12, and 107Ϯ12 bpm (*PϽ0.0009). Left atrial pressure at 8 weeks after MI was similar for control, sACEI, hACEI, AT 1 , and CT, respectively: 10Ϯ2, 11Ϯ2, 10Ϯ3, 11Ϯ2, and 11Ϯ2 mm Hg, PϭNS).
Global LV Remodeling and Function
Baseline, 8 weeks after MI, and change from baseline results are shown for the 5 treatment groups (Table 1) . At baseline, all parameters were similar between groups. The decline in EF associated with postinfarction LV remodeling was significantly less with CT than with sACEI, AT 1 blockade, or control and was also less for hACEI than for control. The increase in EDVI was also less with CT than with AT 1 blockade or control (PϽ0.02), and the increase in ESVI with CT was less than with sACEI, AT 1 blockade, or control (PϽ0.04). In contrast, hACEI changes in EDVI did not differ from other groups, and ⌬ESVI differed only from control (PϽ0.05). AT 1 blockade showed ⌬ESVI and ⌬EDVI very similar to control, but EF was similar to that with sACEI. Both LV EDVI and ESVI at 8 weeks after MI were significantly lower with CT than with no therapy, sACEI, hACEI, or AT 1 blockade. Although the absolute changes in LVMI during the remodeling period were small in all treatment groups, LVMI actually decreased with CT and hACEI. At 8 weeks after MI, LVMI was significantly lower for both CT and hACEI than with no therapy, sACEI, or AT 1 blockade.
Regional Wall Thickness
Representative end-diastolic long-axis images are shown in Figure 1 for all treatment groups. End-diastolic regional wall thickness at 8 weeks after MI was similar for control, sACEI, AT 1 blockade, CT, and hACEI, respectively: infarct, 2Ϯ1, 3Ϯ1, 2Ϯ1, 3Ϯ1, and 3Ϯ1 mm; adjacent myocardium, 6Ϯ1, 7Ϯ1, 6Ϯ1, 7Ϯ1, and 7Ϯ1 mm; and remote myocardium, 9Ϯ1, 10Ϯ2, 9Ϯ1, 10Ϯ2, and 10Ϯ2 mm (PϭNS for all).
Regional LV Function
The results for baseline, 8 weeks after MI, and change from baseline for %S in adjacent noninfarcted myocardial regions are shown in Table 2 . At baseline, %S in future adjacent and remote noninfarcted regions was similar for all groups. Normal heterogeneity was noted, with apical and subendocardial regions showing higher %S than basal and subepicardial regions. 4, 8, 11, 21 At 8 weeks after MI, adjacent %S in the CT group was higher than all other treatment groups, and the decrease from baseline was significantly less with CT than with sACEI, AT 1 blockade, and control. With hACEI, the fall in adjacent %S in subendocardium was less than with sACEI or Control. There were no significant between-group differences in remote myocardial %S at baseline or at 8 weeks after MI.
Discussion
The present study demonstrates that when AT 1 blockade is added to sACEI after transmural anteroapical MI, the combination further attenuates LV remodeling and preserves LV systolic function better than with sACEI alone. The 2 most important prognostic variables predictive of postinfarction mortality, ESVI and EF, 22, 23 are improved with CT (Figure 2A and 2B) compared with sACEI alone, AT 1 antagonism alone, or control. AT 1 antagonism as monotherapy tended to limit postinfarction LV systolic dysfunction, but did not attenuate geometric LV remodeling in this model. Interestingly, treatment with hACEI did provide further benefit compared with sACEI, especially with regard to changes in LVMI. There was a trend favoring CT over hACEI with respect to ⌬ESVI and ⌬EDVI, but this was not statistically significant by ANOVA. Both ESVI and EDVI at 8 weeks after MI were significantly smaller with CT than with all other groups. CT was also superior at limiting adjacent regional systolic dysfunction compared with sACEI, AT 1 blockade, or no therapy. Beneficial effects of CT occurred in the absence of any differences in blood pressure or LV filling pressure between treatment groups, suggesting that the differences were related to direct myocardial effects. Myocardial blood flow and flow reserve are unchanged in adjacent and remote regions at 8 weeks after MI 21 and therefore would not be expected to play a role in this process. We have previously shown that there is no significant myocardial fibrosis qualitatively in adjacent or remote noninfarcted myocardium in untreated infarcted control animals in this model. 8 Quantitative analysis of adjacent and remote region volume percent collagen in untreated infarcted control animals also did not show any evidence of myocardial fibrosis (Sanford P. Bishop, DVM, PhD, unpublished data). Thus, although the myocardial interstitium may play a role in postinfarction remodeling, it is unlikely that differences in the extracellular environment can explain all of the observed results.
Increases in adjacent region LV wall stress in control and sACEI-treated animals, coupled with a reduction in wall stress in the CT group, could contribute to the improved EF and adjacent %S seen with CT. Valid estimation of wall stress in infarcted ventricles with inhomogeneous regional structure and function requires complex finite-element analyses incorporating detailed information on the material properties of each region 24 and is very difficult in vivo. Therefore, at present, we could examine only the geometric determinants of wall stress, namely, wall thickness and ventricular volume. Nonetheless, our previous studies have hypothesized that elevated wall stress is an important determinant of chronic adjacentregional dysfunction. 8 Other indirect evidence of increased regional wall stress is derived from studies assessing wall curvature on a regional basis in the chronic postinfarct LV. 25, 26 Regional thickness and blood pressure were similar between treatment groups in this study, but EDV and ESV (and hence ventricular radii) are reduced with CT compared with controls, AT 1 blockade, and sACEI. Thus, wall stress must be lower by the Laplace relationship and could contribute to improved EF and adjacent %S.
Monotherapy with ACEI has consistently been shown to limit postinfarction LV remodeling in experimental studies as well as in clinical trials. Both direct and indirect actions of the renin-angiotensin system have been implicated in this process. Depending on the model studied, conflicting data exist on the relative importance of reductions in Ang II levels and inhibition of bradykinin breakdown in this process. 14, 15, 27, 28 The ability of ACEI to decrease Ang II synthesis may also be diminished over time by the production of Ang II via non-ACE pathways within the myocardium. 16, 29 In fact, the compensatory increase in Ang I associated with ACEI may drive non-ACE production of Ang II, as evidenced by the nearly normal levels of Ang II found in heart failure patients treated chronically with ACEI. 30 Although the present study suggests that AT 1 antagonism provides additional benefits when added to ACEI after myocardial infarction, it remains unclear whether AT 1 antagonism has an independent effect or merely potentiates the effects of ACEI by offsetting a variety of compensatory mechanisms that normally blunt the effectiveness of ACEI alone.
Comparison With Previous Studies
Conflicting data exist on the effect of AT 1 blockade alone on postinfarction LV remodeling. In a rat coronary ligation model, Schieffer et al 14 found that ACEI and AT 1 blockade were equally effective in limiting postinfarction LV remodeling. Milavetz et al 28 confirmed these findings and showed no difference in survival at 1 year between rats treated with ACEI or an AT 1 antagonist after coronary ligation-induced MI. In an electrical injury canine model, however, McDonald et al 27 found that AT 1 blockade failed to attenuate LV remodeling.
To the best of our knowledge, the effect of combined ACEI and AT 1 blockade on postinfarction LV remodeling has not previously been evaluated. Combination therapy, however, has been evaluated in other experimental and clinical conditions. In a porcine model of rapid pacing-induced congestive heart failure, Spinale et al 17 found that combination therapy provided greater preservation of LV pump function and geometry than ACEI alone. LV end-diastolic dimension was smaller and LV fractional shortening, velocity of circumferential fiber shortening, and cardiac output were all greater with combination therapy than with ACEI alone. These results are consistent with the findings of the present study. Interestingly, AT 1 antagonism alone did not have a beneficial effect on genetic remodeling in this model. Recently, the addition of AT 1 blockade to recommended or maximally tolerated ACEI in patients with heart failure was shown to improve exercise capacity and reduce symptoms. 19 In Val-HeFT, 31 however, the addition of AT 1 blockade to standard heart failure therapy did not improve mortality despite significantly improving EF, quality of life, and NYHA functional class.
Study Limitations
The 10-mg/d dose of ramipril used in the sACEI group was based on previous work in this animal model demonstrating consistent inhibition of ACE activity and attenuation of postinfarction LV remodeling. 11 The 20-mg/d dose of ramipril used in the hACEI group was arbitrary, however, and further effects with even higher doses of ramipril cannot be excluded. The present study does not provide a complete description of the dose-response curves for ACEI, AT 1 antagonism, and their combination in this animal model. Further studies to more completely describe such doseresponse curves would provide important information. The volumetric accuracy and superior reproducibility of cardiac MRI have consistently provided adequate statistical power with similar sample sizes in this model 4, 8, 11, 21 and other models. 15, 17 Nevertheless, the number of study groups did limit statistical power in the present study. Only 1 time point during remodeling was studied. The 8-week-postinfarction time point was chosen on the basis of the time course of remodeling previously demonstrated in this model. 4, 8, 11, 21 Effects beyond this time point may warrant further investigation. Finally, the cellular mechanisms responsible for the additive effects seen with combined ACEI and AT 1 blockade in the present study remain unclear.
A large, multicenter trial that will compare ACEI plus AT 1 blockade, ACEI alone, and AT 1 blockade alone in humans after MI is currently under way. One of the hypotheses underlying this trial is that combined therapy is superior to standard doses of ACEI alone. The results of the present study support that hypothesis.
